Microbiology, sterility testing and microbial ID capabilities enhanced. 

Avista Pharma Solutions, Inc. announced it has completed the comprehensive expansion of its contract testing facility in Agawam, Massachusetts. A result of Avista Pharma’s 2016 capital investment strategy, the improved facility adds 4,200 sq. ft of space and features new microbiology laboratory as well as a modular cleanroom area that houses isolator technology and an ISO 6 cleanroom for medical device, pharmaceutical and biologic sterility testing.

In addition, the company said the laboratory support division has implemented new pass-through autoclaves and labware processing technologies to streamline workflow and complement the company’s suite of microbiology services. “We remain committed to providing best-in-class Microbiology, Analytical Chemistry and Cleanroom services,” said Avista Pharma’s Patrick Walsh, Chief Executive Officer. “This investment will complement our existing capabilities and expand our service offerings for our pharmaceutical and medical device clients.”

According to the company, the facility’s full range of comprehensive services will continue and include raw material and finished product release testing, ICH stability and storage, container closure integrity testing (CCIT), water system testing and validation, cleanroom monitoring and risk assessments, microbial identification via both MicroSEQ^®ID (rapid 16S rDNA sequencing) and Vitek^®MS (MALDI-TOF), mycoplasma testing, Antimicrobial Effectiveness Testing (AET), Microbial Enumeration Testing (MET), endotoxin and bioburden testing and disinfectant efficacy qualifications.